Clinical evaluation of the effectiveness of treatment of the hand-foot syndrome – skin toxicity of antitumor target therapy with multi-kinase inhibitors
https://doi.org/10.14341/serg9704
Abstract
Background. The effective treatment of the hand-foot syndrome is a necessary component of the complex treatment of patients receiving antitumor therapy with multikinase inhibitors.
Aims. The assessment of a new effective method for the treatment of palm-plantar syndrome in patients receiving multi-kinase inhibitors.
Materials and methods. There are 27 patients received antitumor treatment with multi-kinase inhibitors and had clinical manifestations of the hand-foot syndrome (HFS) for observation. The main group (14 patients) used a combination of an alpha-lipoic acid at a dose of 600 mg per day per os and an ointment containing 0.005% calcipotriol and 0.05% betamethasone dipropionate 2 times a day. The control group, included 13 patients, used a combination with a cream containing 10% urea and ointment containing 0.05% betamethasone dipropionate.
Results. After a week of treatment, the regression of the skin process was observed in both groups, but it was more evident in the main group: significant differences in severity of erythema, paresthesia, pain and burning sensation, the Dermatological Life Quality Index (DLQI) were observed at this stage of therapy (p < 0.05). After 2 weeks of therapy: a more positive trend in the main group in terms of erythema, paresthesia and burning, but the most significant difference is DLQI – 17.4 in the main group and 22.8 in the control group (p < 0.0001). At the end of the 3rd week of therapy: differences with the main characteristics of erythema, desquamation, paresthesia (p < 0.0008), pain (p < 0.0001), DLQI (p < 0.0001). At the end point of the study (after 4 weeks of therapy), significant differences were found in reducing the symptoms and the main parameters for evaluating the effectiveness of DLQI in patients of the main group with a reliability of p < 0.0001. The high correlation of DLQI was found with erythema, pain, burning, paresthesia and desquamation.
Conclusions. The treatment of the hand-foot plantar syndrome combined using alpha-lipoic acid inside and topical therapy in the form of an ointment containing calcipotriol and betamethasone dipropionate, can be recommended for patients receiving targeted therapy with multi-kinaseinhibitors.
About the Authors
Evgeniya A. ShatokhinaCentral State Medical Academy; National Research Center for Hematology
Russian Federation
MD, PhD
Larisa S. Kruglova
Central State Medical Academy
Russian Federation
MD, PhD
Oleg A. Shukhov
National Research Center for Hematology
Russian Federation
MD, PhD
References
1. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176-186. doi: https://doi.org/10.1080/02841860701765675.
2. Johnston JB, Navaratnam S, Pitz MW, et al. Targeting the EGFR pathway for cancer therapy. Curr Med Chem. 2006; 13(29):3483-3492. doi: https://doi.org/10.2174/092986706779026174.
3. Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356-358. doi: https://doi.org/10.1016/S2213-8587(13)70215-8.
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2): 125-134. doi: https://doi.org/10.1056/NEJMoa060655.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. doi: https://doi.org/10.1056/NEJMoa065044.
6. Гусев Н.Б. Протеинкиназы: строение, классификация, свойства и биологическая роль. // Соросовский образовательный журнал. – 2000. – Т. 6. – №12. – С. 4-12. [Gusev N.B. Proteinkinazy: stroenie, klassifikatsiya, svoystva i biologicheskaya rol'. Sorosovskiyobrazovatel'nyy zhurnal. 2000;6(12):4-12. (In Russ.)]
7. Шатохина Е.А., Круглова Л.С. Иммунопатогенетические механизмы кожных токсических реакций противоопухолевой терапии мультикиназными ингибиторами ангиогенеза (обзор). // Саратовский научно-медицинский журнал. – 2017. – Т. 13. – №3. – С. 605-611. [Shatokhina EA, Kruglova LS. Immunopathogenetic mechanisms of skin toxic response in antitumor therapy with multikinase of angiogenesis inhibitors (review). Saratov Journal of Medical Scientific Research. 2017;13(3):605-611. (In Russ.)]
8. US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. Rockville: National Cancer Institute; 2009.
9. Румянцев П.О., Волкова М.И., Подвязников С.О., и др. Управление токсичностью ингибиторов ангиогенеза: резолюция совета экспертов. // Эндокринная хирургия. – 2017. – Т. 11. – №3. – С. 157-163. [Rumyantsev PO, Volkova MI, Podvyaznikov SO, et al. Toxicity management of angiogenesis inhibitors: resolution of expert panel. Endocrine surgery. 2017;11(3):157-163. (In Russ.)] doi: https://doi.org/10.14341/serg20173157-163.
10. Шатохина Е.А., Круглова Л.С. Профилактика ладонно-подошвенного синдрома – кожной токсической реакции таргетной терапии больных онкологического профиля. // Кремлевская медицина. – 2018. – №1. – С. 79-83. [Shatokhina EA, Kruglova LS. The prophylaxis of palmar-plantar syndrome – skin toxic reaction of target therapy of oncological patients. Kremlin Medicine Journal. 2018;(1): 79-83. (In Russ.)]
11. Воробьева О.В. Тиоктовая (альфа-липоевая) кислота – спектр клинического применения. // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2011. – Т. 111. – №10. – С. 86-90. [Vorob’eva OV. Thioctic (alpha-lipoic) acid-spectrum of clinical use. Zh Nevrol Psikhiatr ImS S Korsakova. 2011;111(10):86-90. (In Russ.)]
12. Шавловская О.А. Тиоктовая кислота: антиоксидантная терапия неврологических заболеваний. // РМЖ. – 2014. – Т. 22. – №13. – С. 960-965. [Shavlovskaya OA. Tioktovaya kislota: antioksidantnaya terapiya nevrologicheskikh zabolevaniy. Russian Medical Journal.2014;22(13):960-965. (In Russ.)]
13. Королева И.А., Болотина Л.В., Гладков О.А., и др. Практические рекомендации по лекарственному лечению дерматологических осложнений противоопухолевой лекарственной терапии. // Злокачественные опухоли: Практические рекомендации RUSSCO. – 2017. – Т. 7. – №3S2. – С. 514-523. [Koroleva IA, Bolotina LV, Gladkov OA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu dermatologicheskikh oslozhneniy protivoopukholevoy lekarstvennoy terapii. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO. 2017;7(3S2):514-523. (In Russ.)] doi: https://doi.org/10.18027/2224-5057-2017-7-3s2-514-523.
14. Тиоктовая (α-липоевая) кислота. Краткая информация из основных исследований и статей. Доказательная база. – М., 2014. – 15 с. [Tioktovaya (α-lipoevaya) kislota. Kratkaya informaciya iz osnovnyh issledovanij i statej. Dokazatel'naya baza. Moscow; 2014: 15. (In Russ.)]
Supplementary files
|
1. Fig. 1. Palmar and plantar syndrome, lesion of palms of I degree. | |
Subject | ||
Type | Исследовательские инструменты | |
View
(882KB)
|
Indexing metadata ▾ |
|
2. Fig. 2. Palmar and plantar syndrome, lesion of feet II. | |
Subject | ||
Type | Исследовательские инструменты | |
View
(636KB)
|
Indexing metadata ▾ |
Review
For citations:
Shatokhina E.A., Kruglova L.S., Shukhov O.A. Clinical evaluation of the effectiveness of treatment of the hand-foot syndrome – skin toxicity of antitumor target therapy with multi-kinase inhibitors. Endocrine Surgery. 2018;12(3):140-149. (In Russ.) https://doi.org/10.14341/serg9704

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).